Dietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating Peroxisome proliferator-activated receptor-γ

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Lewis, Stephanie N ^a,b   Brannan, Lera ^a   Guri, Amir J ^b   Lu, Pinyi ^a,b   Hontecillas, Raquel ^b   Bassaganya Riera, Josep ^a,b   Bevan, David R ^a,b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ELEOSTEARIC ACID; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; STEARIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ELEOSTEARIC ACID; LINOLENIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG SCREENING; DRUG TARGETING; ENTERITIS; LIGAND BINDING; MACROPHAGE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PHARMACOPHORE; PHENOTYPE; PREDICTION; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR UPREGULATION; STEREOISOMERISM; ANIMAL; CELL LINE; DRUG POTENTIATION; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

MUS;

ANIMALS; CELL LINE; INFLAMMATORY BOWEL DISEASES; LINOLENIC ACIDS; MICE; PPAR GAMMA; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 80052312139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024031     Document Type: Article

References (75)

1. Wahli W, (2008) A gut feeling of the PXR, PPAR, and NF-kB connection. Journal of Internal Medicine 263: 613-619.
2. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, et al. (2006) PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55: 1341-1349.
3. Gani OABSM, Sylte I, (2009) Molecular recognition of long chain fatty acids by peroxisome proliferator-activated receptor α. Medicinal Chemistry Research 18: 8-19.
4. Guri AJ, Hontecillas R, Ferrer G, Casagran O, Wankhade U, et al. (2008) Loss of PPARγ in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. Journal of Nutritional Biochemistry 19: 216-228.
5. Huang TH-W, Teoh AW, Lin B-L, Lin DS-H, Roufogalis B, (2009) The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacological Research 60: 195-206.
6. Reiss AB, Vagell ME, (2006) PPARγ Activity in the Vessel Wall: Anti-Atherogenic Properties. Current Medicinal Chemistry 13: 3227-3238.
7. Wu GD, (2003) Is There a Role for PPARgamma in IBD? Yes, No, Maybe. Gastroenterology 124: 1538-1542.
8. Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, et al. (2004) Activation of PPARγ and δ by Conjugated Linoleic Acid Mediates Protection From Experimental Inflammatory Bowel Disease. Gastroenterology 127: 777-791.
9. Martin H, (2009) Role of PPAR-gamma in inflammataion. Prospects for therapeutic intervention by food components. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 669: 1-7.
10. Tontonoz P, Spiegelman BM, (2008) Fat and Beyond: The Diverse Biology of PPARγ. Annual Review of Biochemistry 77: 289-312.
11. Ricote M, Li A, Willson TM, Kelly C, Glass C, (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82.
12. Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, et al. (2004) Infliximab in inflammtory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53: 849-853.
13. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trail. The Lancet 359: 1541-1549.
14. Goldsmith P, McGarity M, Walls AF, Church MK, Millward-Sadler GH, et al. (1990) Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Digestive Diseases and Sciences 35: 1409-1413.
15. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W, (2006) American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease. Gastroenterology 130: 940-987.
16. Compston JE, (1995) Review article: osteoporosis, corticosteroids, and inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 9: 237-250.
17. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, et al. (2008) Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial. Gastroenterology 134: 688-659.
18. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al. (2003) Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure. Circulation 108: 2941-2948.
19. Bassaganya-Riera J, Hontecillas R, (2006) CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clinical Nutrition 25: 454-465.
20. Guri AJ, Hontecillas R, Bassaganya-Riera J, (2010) Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration. Clinical Nutrition 29: 824-831.
21. Hontecillas R, Wannemeulher M, Zimmerman D, Hutto D, Wilson J, et al. (2002) Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. Journal of Nutrition 132: 2019-2027.
22. Klebe G, (2006) Virtual ligand screening: strategies, perspectives and limitations. Drug Discovery Today 11: 580-594.
23. Hontecillas R, Diguardo M, Duran E, Orpi M, Bassaganya-Riera J, (2008) Catalpic acid decreases abdominal fat deposition, improves glucose homeostasis and upregulates PPAR alpha expression in adipose tissue. Clinical Nutrition 27: 764-772.
24. Hontecillas R, O'Shea M, Einerhand A, Diguardo M, Bassaganya-Riera J, (2009) Activation of PPAR(gamma) and (alpha) by Punicic Acid Ameliorates Glucose Tolerance and Suppresses Obesity-Related Inflammation. Journal of the American College of Nutrition 28: 184-195.
25. Badami R, Patil K, (1980) Structure and occurrence of unusual fatty acids in minor seed oils. Progress in Lipid Research 19: 119-153.
26. Tsuzuki T, Kawakami Y, (2008) Tumor angiogenesis suppression by alpha-eleostearic acid, a linoleic acid isomer with a conjugated triene system, via peroxizome proliferator-activated receptor gamma. Carcinogenesis 29: 797-806.
27. Moon H-S, Guo D-D, Lee H-G, Choi Y-J, Kang J-S, et al. (2009) Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγ and inhibition of ERK1/2. Cancer Science 101: 396-402.
28. Tsuzuki T, Tokuyama Y, Igarashi M, Miyazawa T, (2004) Tumor growth suppression by α-eleostearic acid, a linoleic acid isomer with a conjugated triene system, via lipid peroxidation. Carcinogenesis 25: 1417-1425.
29. Eom J-M, Seo M-J, Baek J-Y, Chu H, Han SH, et al. (2009) Alpha-eleostearic acid induces autophagy-dependent cell death through targeting AKT/mTOR and ERK1/2 signal together with the generation of reactive oxygen species. Biochemical and Biophysical Research Communications 391: 903-908.
30. Yuan G-F, Wahlqvist ML, Yuan J-Q, Wang Q-M, Li D, (2009) Effect of Punicic Acid Naturally Occuring in Food on Lipid Peroxidation in Healthy Young Humans. Journal of the Science of Food and Agriculture 89: 2331-2335.
31. Boussetta T, Raad H, Letteron P, Gougerot-Pocidalo M-A, Marie J-C, et al. (2009) Punicic Acid a Conjugated Linolenic Acid Inhibits TNFα-Induced Neutrophil Hyperactivation and Protects from Experimental Colon Inflammation in Rats. PLoS One 4.
32. Vroegrijk I, van Diepen J, van den Berg S, Westbroek I, Keizer H, et al. (2011) Pomegranate seed oil, punicic acid prevents diet-induced obesity and insulin resistance in mice. Food and Chemical Toxicology In press.
33. Meerts IA, Verspeek-Rip CM, Buskens CA, Keizer HG, Bassaganya-Riera J, et al. (2009) Toxicology evaluation of pomegranate seed oil. Food and Chemical Toxicology 47: 1085-1092.
34. Bassaganya-Riera J, Diguardo M, Climent M, Vives C, Carbo A, et al. (2011) Activation of PPAR γ and δ by dietary punicic acid ameliorates intestinal inflammation in mice. British Journal of Nutrition In Press.
35. Saha SS, Ghosh M, (2009) Comparative study of antioxidant activity of a-eleostearic acid and punicic acid against oxidative stress generated by sodium arsenite. Food and Chemical Toxicology 47: 2551-2556.
36. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 19: 1639-1662.
37. Trott O, Olson AJ, (2010) AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading. Journal of Computational Chemistry 31: 455-461.
38. Berman HM, Battistuz T, Bhat TN, Bluhm W, Bourne PE, et al. (2002) The Protein Data Bank. Acta Crystallographica Section D: Biological Crystallography D58: 899-907.
39. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Research 28: 235-242.
40. Gampe RT, Montana VG, Lambert MH, Miller AB, Bledsoe RK, et al. (2000) Asymmetry in the PPARg/RXRa Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors. Molecular Cell 5: 545-555.
41. van der Spoel D, Lindahl E, Hess B, van Buuren AR, Apol E, et al. (2005) Gromacs User Manual version 3.3.
42. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395: 137-143.
43. Li Y, Kovach A, Suino-Powell K, Martynowski D, Xu HE, (2008) Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1alpha. Journal of Biological Chemistry 283: 19132-19139.
44. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, et al. (2008) Structure of the intact PPAR-γ-RXR-α nuclear receptor complex on DNA. Nature 456: 350-357.
45. Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry 25: 1605-1612.
46. Mahindroo N, Wang C-C, Liao C-C, Huang C-F, Lu I-L, et al. (2006) Indol-1-yl Acetic Acids as Peroxisome Proliferator-Activated Receptor Agonists: Design, Synthesis, Structural Biology, and Molecular Docking Studies. Journal of Medicinal Chemistry 49: 1212-1216.
47. Mahindroo N, Peng Y-H, Lin C-H, Tan UK, Prakash E, et al. (2006) Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. Journal of Medicinal Chemistry 49: 6421-6424.
48. Pochetti G, Godio C, Mitro N, Caruso D, Galmozzi A, et al. (2007) Insights into the Mechanism of Partial Agonism: Crystal Structures of the Peroxisome Proliferator-Activated Receptor γ Ligand-Binding Domain in the Complex with Two Enantiomeric Ligands. Journal of Biological Chemistry 282: 17314-17324.
49. Itoh T, Louise F, Amin K, Inaba Y, Szanto A, et al. (2008) Structural basis for the activation of PPARγ by oxidized fatty acids. Nature Structural & Molecular Biology 15: 924-931.
50. Artis DR, Lin JJ, Wang W, Mehra U, Perreault M, et al. (2009) Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. PNAS 106: 262-267.
51. Waku T, Shiraki T, Oyama T, Fujimoto Y, Maebara K, et al. (2009) Structural Insight into PPARγ Activation Through Covalent Modification with Endogenous Fatty Acids. Journal of Molecular Biology 385: 188-199.
52. Salam NK, Huang TH-W, Kota BP, Kim MS, Li Y, et al. (2008) Novel PPAR-gamma Agonists Identified from a Natural Product Library: A Virtual Screening, Induced-Fit Docking and Biological Assay Study. Chemical Biology & Drug Design 71: 57-70.
53. Tanrikulu Y, Rau O, Schwarz O, Proschak E, Siems K, et al. (2009) Structure-Based Pharmacophore Screening for Natural-Product-Derived PPARγ Agonists. ChemBIoChem 10: 75-78.
54. Kuroda M, Mimaki Y, Honda S, Tanaka H, Yokota S, et al. (2010) Phenolics from Glycyrrhiza glabra roots and their PPAR-γ ligand-binding activity. Bioorganic & Medicinal Chemistry 18: 962-970.
55. Markt P, Schuster D, Kirchmair J, Laggner C, Langer T, (2007) Pharmacophore modeling and parallel screening for PPAR ligands. Journal of Computer-Aided Molecular Design 21: 575-590.
56. Schuettelkopf A, van Aalten D, (2004) PRODRG- a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica D60: 1355-1363.
57. Kellenberger E, Rodrigo J, Muller P, Rognan D, (2004) Comparative Evaluation of Eight Docking Tools for Docking and Virtual Screening Accuracy. Proteins 57.
58. Moreland JL, Gramada A, Buzko OV, Zhang Q, Bourne PE, (2005) The Molecular Biology Toolkit (MBT): a modular platform for developing molecular visualization applications. BMC Bioinformatics 6: 1-7.
59. Schwartz RL, Phoenix T, Foy BD, (2008) Learning Perl. 5th ed ed: O'Reilly Media, Inc.
60. Bassaganya-Riera J, Guri AJ, Lu P, Climent M, Carbo A, et al. (2011) Abscisic Acid Regulates Inflammation via Ligand-Binding Domain-Independent Activation of PPAR gamma. Journal of Biological Chemistry 286: 2504-2516.
61. Guri AJ, Hontecillas R, Si H, Liu D, Bassaganya-Riera J, (2007) Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diests. Clinical Nutrition 26: 107-116.
62. Bassaganya-Riera J, Ferrer G, Casagran O, Sanchez S, de Horna A, et al. (2009) F4/80hiCCR2hi macrophage infiltration into the intra-abdominal fat worsens the severity of experimental IBD in obese mice and DSS colitis. e-SPEN, European e-Journal of Clinical Nutrition and Metabolism 4: e90-e97.
63. Chang MW, Ayeni C, Breuer S, Torbett BE, (2010) Virtual Screening for HIV Protease Inhibitors: A Comparison of AutoDock 4 and Vina. PLoS One 5: e11955.
64. Bassaganya-Riera J, Guri AJ, Hontecillas R, (2011) Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists. Journal of Obesity pp. 1-7.
65. Shah Y, Morimura K, Gonzalez F, (2007) Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. American Journal of Physiology, Gastrointestinal and Liver Physiology 292: G657-666.
66. Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink RP, et al. (2007) The PPARg Agonist Rosiglitazone impairs colonic inflammation in mice with experimental colitis. Journal of Clinical Immunology 27: 275-283.
67. Mohapatra SK, Guri AJ, Climent M, Vives C, Carbo A, et al. (2010) Immunoregulatory Actions of Epithelial Cell PPARγ at the Colonic Mucosa of Mice with Experimental Inflammatory Bowel Disease. PLoS One 5: e10215.
68. Zhang T, Gao Y, Mao Y, Zhang Q, Lin C, et al. (2011) Growth inhibition and apoptotic effect of alpha-eleostearic acid on human breast cancer cells. Journal of Natural Medicines pp. 1-8.
69. Popovich DG, Lee Y, Li L, Zhang W, (2011) Momordica charantia Seed Extract Reduced Pre-Adipocyte Viability, Affects Lactate Dehydrogenase Release, and Lipid Accumulation in 3T3-L1 Cells. Journal of Medicinal Food 14: 201-208.
70. Yasui Y, Hosokawa M, Sahara T, Suzuki R, Ohgiya S, et al. (2005) Bitter gourd seed fatty acid rich in 9c, 11t, 13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53, and PPARγ in human colon cancer Caco-2 cells. Prostaglandins, Leukotrienes, and Essential Fatty Acids 73: 113-119.
71. Hennessy AA, Ross RP, Devery R, Stanton C, (2011) The Health Promoting Properties of the Conjugated Isomers of α-Linoleic Acid. Lipids 46: 105-119.
72. Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, et al. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127: 777-791.
73. Tran HNA, Bae S-Y, Song B-H, Lee B-H, Bae Y-S, et al. (2010) Pomegranate (Punica granatum) seed linolenic acid isomers: Concentration-dependent modulation of estrogen receptor activity. Endocrin Research 35: 1-16.
74. Hayhurst GP, Lee Y-H, Lambert G, Ward JM, Gonzalez FJ, (2001) Hepatocyte Nuclear Factor 4a (Nuclear Receptor 2A1) is Essential for Maintenance of Hepatic Gene Expression and Lipid Homeostasis. Molecular and Cellular Biology 21: 1393-1403.
75. Nagao K, Yanagita T, (2008) Bioactive lipids in metabolic syndrome. Progress in Lipid Research 47: 127-146.